OncoCount: A New Era in Cancer Screening

When it comes to cancer, early detection makes all the difference. Traditional screening methods like imaging and biopsies often identify disease only after it has formed, but what if it were possible to detect signs of cancer activity earlier, through a simple blood test?

The OncoCount test, developed by RGCC (Research Genetic Cancer Centre), does exactly that. It measures circulating tumor cells (CTCs), cancer cells that have broken away from a tumor and entered the bloodstream. By detecting these cells early, OncoCount provides valuable insight into your body's cellular health, helping you stay ahead with proactive, preventive screening.

Understanding Circulating Tumor Cells (CTCs)

CTCs are cancer cells that have detached from a tumor and are circulating in the bloodstream. Although they may be few in number, they carry important information about cancer activity and progression.

Their presence typically points to active tumor processes somewhere in the body, even when no visible tumor has been detected through imaging. That's what makes them such a powerful biomarker for early detection and ongoing monitoring.

By analyzing CTCs, doctors can gain insight into cancer biology without invasive biopsies, giving a clearer view of what's happening at a cellular level.

Proactive Screening and Annual Health Checks

OncoCount represents a new approach to health screening, one that focuses on prevention, not reaction.

For individuals seeking to take control of their health, adding OncoCount to your annual wellness check can provide reassurance and early insight into your body's cellular activity. Because CTCs can appear before a tumor becomes visible, the test serves as an early warning that may detect changes long before symptoms arise. It can be particularly valuable for:

• Individuals with a family history of cancer
• Those with lifestyle or occupational risk factors
• People looking to include comprehensive cancer screening as part of their yearly health routine

By monitoring CTC levels over time, you can track your cellular health year after year. A proactive way to safeguard your long-term well-being.

Curious How Early Detection Works?

View the OncoCount Sample Report to see how circulating tumor cells are identified and analyzed in a simple blood test.

How the OncoCount Test Works

The process is simple and entirely non-invasive.

A small blood sample is collected and analyzed using flow cytometry and negative selection techniques to isolate circulating tumor cells while maintaining their genetic and molecular integrity.

The test quantifies the number of CTCs present in each millilitre of blood. Elevated levels may indicate active tumor presence, while low or undetectable counts can suggest successful treatment or remission. Because the test is non-invasive and repeatable, it can be used for both preventive annual screening and ongoing monitoring.

The Science Behind CTC Detection

Scientific research consistently reinforces the value of circulating tumor cells as predictive biomarkers. Studies have shown that fluctuations in CTC levels correlate with treatment outcomes and recurrence risk. CTC testing, sometimes called a "liquid biopsy", captures cancer's biological footprint directly from the blood. It allows clinicians to study tumor behavior in real time, supporting earlier, more informed decision-making in both prevention and treatment.

What Makes OncoCount Unique

Developed by RGCC, OncoCount stands out for its precision and global standardization. The test isolates viable tumor cells with high purity, providing reliable data for ongoing health management.

• Broad Applicability: Suitable for most solid tumors (except central nervous system cancers, which do not release CTCs).
• Highly Specific: Uses advanced techniques to distinguish CTCs from normal blood cells.
• Safe & Repeatable: Can be performed periodically as part of an annual health program or ongoing follow-up.

By integrating molecular precision with accessibility, OncoCount represents a new step forward in preventive oncology.

Where OncoCount Fits in Cancer Care

While OncoCount offers tremendous promise for early detection, it also plays a crucial role in personalized cancer management, from establishing baselines during treatment to monitoring patients in remission:

Establishing a Baseline

• OncoCount is most powerful when used to create a baseline and then track changes over time. This baseline can be established in two common situations

At diagnosis or before starting treatment

• The initial CTC count provides a biological reference point. Studies have shown that higher baseline CTC counts often correlate with poorer outcomes, whereas reductions in CTCs after treatment are associated with improved survival.
• For instance, in metastatic breast cancer, patients whose CTCs fell from greater than 5 to less than 5 per 7.5 mL of blood after starting therapy had markedly better progression-free and overall survival - emphasizing that changes in CTC levels over time are more predictive than a single measurement.

After treatment or once in remission

• A "post-treatment baseline" helps track the body's recovery and monitor for recurrence. Detectable CTCs in follow-up blood samples may precede imaging findings by months, making periodic testing a valuable adjunct in survivorship care.
• In practical terms, CTC counts provide a biological readout of tumor activity. Declining levels after therapy suggest a good response, while re-emergence of detectable cells may signal the need for closer clinical evaluation.

Monitoring During Treatment

• Once a baseline is established, routine OncoCount testing helps assess treatment effectiveness.
• Falling CTC levels following therapy are linked to improved outcomes and longer survival across several cancer types.
• Conversely, persistently elevated or rising counts during treatment may indicate reduced therapeutic efficacy and prompt clinicians to review or adjust treatment plans.
• RGCC generally recommends testing every three months while active disease is present, allowing for responsive, data-driven care. Frequency should always be tailored by a physician to each patient's risk profile.

Monitoring in Remission

• For patients who have completed treatment and are in remission, periodic OncoCount testing can function as an early-warning of potential recurrence.
• Clinical studies demonstrate that a positive CTC result during follow-up correlates with a higher risk of recurrence and reduced survival rates in several cancer types. This makes ongoing CTC surveillance an invaluable complement to conventional imaging.
• RGCC suggests testing every six months once remission is confirmed and stability has been shown across two to three consecutive tests, though frequency should always be tailored by a physician to each patient's risk profile.

Limitations and Considerations

While CTC testing is powerful, it's important to understand its limitations.

According to RGCC, OncoCount cannot detect:

• Cancers of the brain or central nervous system (CNS)
• Encapsulated tumors that do not release cells into the bloodstream
• Dormant tumor cells not currently circulating
• It should therefore be viewed as a complementary tool, best used alongside imaging, pathology, and other laboratory evaluations.

Taking a Proactive Step Toward Prevention

Incorporating OncoCount into your annual health screening empowers you to move from reactive to preventive care. It's a simple, non-invasive way to understand your body's cellular health and catch early signs of cancer-related activity; potentially years before traditional methods can.

Book your OncoCount Test through Kelter today to include this advanced cancer screening test as part of your annual health check, all from the comfort of home.

Key Takeaways

• OncoCount detects and quantifies circulating tumor cells (CTCs) in the bloodstream.
• The presence of CTCs generally indicates active tumor processes in the body.
• Designed for early detection and annual screening, OncoCount helps identify potential cancer activity before symptoms arise.
• Establishing a baseline CTC count enables personalized tracking of treatment response and remission.
• A safe, non-invasive, and repeatable test that complements standard cancer diagnostics.

References

1. Nature - Circulating Tumor Cells: Biology and Clinical Significance
2. Nature - Circulating Tumor Cells: A Liquid Fingerprint of Cancer
3. The Lancet Oncology - Clinical Relevance of Circulating Tumour Cells in Solid Tumours
4. National Cancer Institute - Circulating Tumor Cells: Emerging Insights in Oncology
5. Clinical Cancer Research - Prognostic Significance of Circulating Tumor Cells in Cancer
6. MDPI Cancers - The Role of Circulating Tumor Cells as a Liquid Biopsy for Cancer
7. Biomarker Research - Detection of Circulating Tumor Cells: Opportunities and Challenges
8. PubMed - Circulating Tumor Cells as Liquid Biopsy Markers in Cancer Patients
9. RGCC International - OncoCount Test Overview and Sample Report (2023)
10. RGCC SEA - CTC Cancer Tests and Methodology Description
11. Mayo Clinic - Cancer Screening: Finding Cancer Early
12. Nature Breast Cancer Review - CTC Dynamics and Prognostic Value in Metastatic Disease
13. Clinical Cancer Research (2023) - CTC Reduction and Survival Outcomes in Metastatic Breast Cancer
14. Aging-US (2022) - CTC Positivity Predicting Recurrence Prior to Imaging
15. RGCC Internal Guidelines - Suggested Monitoring Cadence: Active Treatment and Remission

Disclaimer

This article is intended for general informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider regarding any medical condition or before making changes to your health routine.